COEPTIS announces strategic tech hub in India

WEXFORD, Pa. - COEPTIS, Inc. (NASDAQ:COEP), a biopharmaceutical and technology company valued at $31.21 million, has unveiled a new technology hub in India, a move aimed at bolstering its capabilities in artificial intelligence (AI) and blockchain technology. The hub, created in partnership with NexGenAI Solutions Group and Ishvara Tech Consulting LLP, is designed to foster innovation and facilitate collaborative projects in AI, blockchain, and defense technologies. According to InvestingPro analysis, the company currently trades above its Fair Value, with investors showing strong interest as evidenced by a 133% price surge over the past six months.

The facility, operated by Ishvara Tech Consulting, will focus on research and development, execution of AI marketing strategies, and crypto initiatives. This strategic expansion is expected to leverage India’s technology ecosystem and skilled workforce to accelerate the development of AI-powered marketing solutions and blockchain applications.

Dave Mehalick, CEO of COEPTIS, remarked on the significance of the expansion, stating that the partnership will combine local expertise with technical strength, potentially speeding up the delivery of new technology offerings.

COEPTIS has recently achieved a string of successes, including the acquisition of the NexGenAI Affiliates Network platform and securing contracts amounting to $2.3 million in new business. These developments underscore the company’s strategy to tap into the growing opportunities in biotechnology and defense sectors. InvestingPro data reveals some financial challenges, with a current ratio of 0.23 indicating potential liquidity concerns. Subscribers can access 8 additional key ProTips about COEPTIS’s financial health and growth prospects.

The India hub is set to support initiatives such as product and service expansion, integration of the NXG Token across digital platforms, and exploration of monetization strategies rooted in data analytics and blockchain innovation.

The NexGenAI Affiliates Network, owned by COEPTIS, is an AI-powered affiliate marketing platform that aims to optimize marketing efforts through automation and advanced analytics.

The new facility in India boasts a 60-seat capacity, expandable to 100, with a modern layout, high-speed fiber optic internet, and advanced security systems to ensure the confidentiality of operations.

COEPTIS, headquartered in Wexford, PA, is dedicated to advancing its mission within the regulatory framework of the FDA, focusing on developing cell therapy platforms for cancer, autoimmune, and infectious diseases, as well as enhancing operational capabilities through advanced technologies. The company’s stock exhibits unique market behavior with a beta of -0.67, suggesting it often moves contrary to broader market trends. For comprehensive analysis and detailed metrics, investors can explore InvestingPro’s extensive financial toolkit.

This announcement is based on a press release statement and contains forward-looking statements that involve risks and uncertainties. Investors are cautioned not to place undue reliance upon any forward-looking statements.

In other recent news, Coeptis Therapeutics Holdings, Inc. has announced the departure of its Chief Scientific and Medical Officer, Colleen Delaney. Delaney, who joined the company in August 2023, is leaving to pursue other opportunities but will continue to provide consulting services during a transition period. Meanwhile, Coeptis has formed a new majority-owned subsidiary, GEAR Therapeutics, Inc., to advance a novel cell therapy platform for cancer treatment. This development follows Coeptis’ acquisition of exclusive rights to the Gene Edited Antibody Resistant (GEAR) Cell Therapy Platform. Additionally, Coeptis has entered a strategic partnership with MarketLeverage to enhance affiliate marketing using AI technology, aiming to improve campaign optimization and data-driven insights. Coeptis has also launched COEP Venture Group to invest in startups focusing on AI and automation technologies, offering capital and strategic mentorship. The company has rebranded to COEPTIS, reflecting a strategic shift to integrate technology and AI alongside its biopharmaceutical activities. This rebranding includes the creation of a new Technology Division and the acquisition of the NexGenAI Affiliates Network platform. These recent developments demonstrate Coeptis’s commitment to innovation and expansion into new technological and therapeutic areas.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.